ArticleFrontiers in immunology2025

Reduced tolerogenic factor sCD83 in NMOSD and relapsing MOGAD: a potential new therapeutic pathway.

Ariel Rechtman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.